Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice
Open Access
- 31 January 2026
- journal article
- Published by Wiley in FEBS Open Bio
- Vol. 16 (7) , 1328-1339
Abstract
Obesity‐related liver disease remains a critical global health challenge, underscoring the need to elucidate the molecular mechanisms underlying hepatic inflammation and metabolic dysfunction, and to identify novel therapeutic targets. This study aimed to determine whether erythropoietin (EPO) modulates soluble epoxide hydrolase (sEH) and lipid mediator pathways to ameliorate hepatic inflammation and metabolic dysfunction in high‐fat diet (HFD)‐induced obese mice. Male C57BL/6 mice were fed HFD with or without EPO treatment, and metabolic phenotyping, including glucose tolerance testing and homeostasis model assessment of insulin resistance, was performed. Hepatic histology and quantitative real‐time polymerase chain reaction were conducted, together with flow cytometry to assess macrophage polarization, western blotting for sEH, and targeted liquid chromatography–tandem mass spectrometry profiling of cytochrome P450 epoxygenase‐derived epoxides. EPO treatment improved glucose metabolism, reduced hepatic steatosis, lowered Ccr2 , Mcp1 , and Tnfα expression, promoted a shift of hepatic macrophages toward an M2 (anti‐inflammatory) phenotype, downregulated hepatic sEH protein levels, and increased both hepatic and plasma concentrations of epoxygenase‐derived epoxides. These findings indicate that EPO suppresses hepatic sEH and favors pro‐resolving lipid mediator signaling, suggesting a potential therapeutic avenue for obesity‐related hepatic inflammation.Keywords
Funding Information
- Japan Foundation for Pediatric Research (21‐006)
- Japan Society for the Promotion of Science (22K15926)
- Japan Society for the Promotion of Science (22K15949)
- Japan Society for the Promotion of Science (22K17806)
- Japan Society for the Promotion of Science (25K11156)
This publication has 47 references indexed in Scilit:
- From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver diseaseJournal of Lipid Research, 2023
- Soluble Epoxide Hydrolase Hepatic Deficiency Ameliorates Alcohol-Associated Liver DiseaseCellular and Molecular Gastroenterology and Hepatology, 2021
- PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in miceBiochemical and Biophysical Research Communications, 2020
- Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathwayBiochemical and Biophysical Research Communications, 2019
- Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approachEuropean Journal of Pharmaceutical Sciences, 2018
- Erythropoietin alleviates hepatic steatosis by activating SIRT1-mediated autophagyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2018
- RORα Induces KLF4-Mediated M2 Polarization in the Liver Macrophages that Protect against Nonalcoholic SteatohepatitisCell Reports, 2017
- Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2015
- Lipid signaling in adipose tissue: Connecting inflammation & metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2015
- Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS‐Induced Cardiac DysfunctionJournal of Cellular Physiology, 2015